Nanomedical strategy to prolong survival period, heighten cure rate, and lower systemic toxicity of S180 mice treated with MTX/MIT

References

• LünenbürgerHLanvers-KaminskyCLechtapeBFrühwaldMCSystematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell linesAnticancer Drugs20102151452220147838
   PubMed Web of Science ®Google Scholar
• VolkELRohdeKRheeMMethotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug effluxCancer Res200060133514352110910063
   PubMed Web of Science ®Google Scholar
• SenguptaSEavaroneDCapilaITemporal targeting of tumour cells and neovasculature with a nanoscale delivery systemNature200543656857216049491
   PubMed Web of Science ®Google Scholar
• ShinHCAlaniAWRaoDARockichNCKwonGSMulti-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugsJ Control Release2009140329430019409432
   PubMed Web of Science ®Google Scholar
• DoughtyJCKaneECookeTGMcArdleCSMitoxantrone and methotrexate chemotherapy with and without mitomycin C in the regional treatment of locally advanced breast cancerBreast2002111979914965654
   PubMed Web of Science ®Google Scholar
• KumarAEffectiveness of mitoxantrone and oral methotrexate combination therapy in relapsing-remitting multiple sclerosisJ Neurol Sci2009285S1S155S339
   Google Scholar
• KadiaTMKantarjianHMThomasDAPhase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemiaAm J Hematol201590212012425368968
   PubMed Web of Science ®Google Scholar
• UkmarTMaverUPlaninšekOKaučičVGaberščekMGodecAUnderstanding controlled drug release from mesoporous silicates: theory and experimentJ Control Release2011155340941721763374
   PubMed Web of Science ®Google Scholar
• RossatoLGCostaVMDallegraveECumulative mitoxantrone-induced haematological and hepatic adverse effects in a subchronic in vivo studyBasic Clin Pharmacol Toxicol2014114325426224119282
   PubMed Web of Science ®Google Scholar
• PintoCMarinoAManziniVDPSequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1)Lung Cancer200652219920616542747
   PubMed Web of Science ®Google Scholar
• SteinRCBowerMLawMMitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trialEuropean Journal of Cancer199228A12196319651419290
   PubMed Web of Science ®Google Scholar
• PintoCMarinoAGuaraldiMCombination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM Regimen) in malignant pleural mesothelioma: a phase II studyAm J Clin Oncol200124214314711319288
   PubMed Web of Science ®Google Scholar
• Harper-WynneCEnglishJMeyerLRandomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breastBr J Cancer199981231632210496359
   PubMed Web of Science ®Google Scholar
• KakolyrisSSamonisGKoukourakisMFirst-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancerAm J Clin Oncol199922327327710362335
   PubMed Web of Science ®Google Scholar
• LeeCKGebskiVJCoatesASTradeoffs in quality of life and survival with chemo-therapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneSpringerplus2013239140024024086
   PubMedGoogle Scholar
• Di BonaEPoglianiERossiGTransplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone and methotrexate-based regimen in 36 patientsLeuk Lymphoma200546687988416019533
   PubMed Web of Science ®Google Scholar
• RigacciLCarraiVNassiLCombined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up studyCancer2005103597097715666323
   PubMed Web of Science ®Google Scholar
• PectasidesDMylonakisAAntoniouFChemotherapy with methotrexate, carbo-platin, mitoxantrone (Novantrone) and vincristine (Oncovin) in transitional-cell urothelial cancerOncology19985521391449499188
   PubMed Web of Science ®Google Scholar
• RainaVSharmaADeoSVMitoxantrone, mitomycin-C, methotrexate combination chemotherapy with radiotherapy and/or surgery in stage III (T4B, NO-2, M0) breast cancerJ Assoc Physicians India1998461192692911229215
   PubMedGoogle Scholar
• van OutryveSSchrijversDvan den BrandeJMethotrexate-associated liver toxicity in a patient with breast cancer: case report and literature reviewNeth J Med200260521622212365478
   PubMed Web of Science ®Google Scholar
• ConwayDCohenJACombination therapy in multiple sclerosisLancet Neurol20109329930820170843
   PubMed Web of Science ®Google Scholar
• LammersTImproving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulationsAdv Drug Deliv Rev201062220323019951732
   PubMed Web of Science ®Google Scholar
• KrishnamachariYSalemAKInnovative strategies for codelivering antigens and CpG oligonucleotidesAdv Drug Deliv Rev200961320521719272328
   PubMed Web of Science ®Google Scholar
• PasquierEKavallarisMAndréNMetronomic chemotherapy: new rationale for new directionsNature Reviews Clinical Oncology201078455465
   PubMed Web of Science ®Google Scholar
• MasciGLosurdoAGandiniCLow-dose “metronomic chemotherapy” with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefitEcancermedicalscience20126127523130087
   PubMedGoogle Scholar
• MaTYLiuLYuanZYDirect synthesis of ordered mesoporous carbonsChem Soc Rev20134293977400323132523
   PubMed Web of Science ®Google Scholar
• Giménez-BonaféPTortosaAPérez-TomásROvercoming drug resistance by enhancing apoptosis of tumor cellsCurr Cancer Drug Targets20099332034019442052
   PubMed Web of Science ®Google Scholar
• KunjachanSBłaużAMöckelDOvercoming cellular multidrug resistance using classical nanomedicine formulationsEuropean Journal of Pharmaceutical Sciences Official Journal of the European Federation for Pharmaceutical Sciences201245442142821907796
   PubMed Web of Science ®Google Scholar
• YadaKShibataKMatsumotoTOhtaMYokoyamaSKitanoSProtease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cellsJ Surg Oncol2005892798515660373
   PubMed Web of Science ®Google Scholar
• PimentaDCChenVCChaoJAlpha1-antichymotrypsin and kallistatin hydrolysis by human cathepsin DJournal of Protein Chemistry200019541141811131147
   PubMedGoogle Scholar
• ChungTHWuSHYaoMThe effect of surface charge on the uptake and biological function of mesoporous silica nano-particles in 3T3-L1 cells and human mesenchymal stem cellsBiomaterials200728192959296617397919
   PubMed Web of Science ®Google Scholar
• HuangXTengXChenDTangFHeJThe effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell functionBiomaterials201031343844819800115
   PubMed Web of Science ®Google Scholar